Campaign News
Need for increased awareness of eating disorder prevalence in high-performance sport
The Australian Institute of Sport (AIS) has this week (Monday, September 7) announced a partnership with the National Eating Disorders Collaboration (NEDC) to call for increased awareness of the prevalence of eating disorders in high-performance sport. The two peak bodies have issued a joint position statement and supporting resources comprising a toolkit for sporting organisations…
Read MoreVIVA!’s COVID Comms Cast harnessing their health communications expertise “for good”
In response to the rapidly evolving COVID-19 pandemic, and to give back to the Australian health + wellness community, independent health + wellness PR agency, VIVA! Communications (VIVA!), has today (May 4, 2020) launched the ‘COVID Comms Cast’. Comprising VIVA!’s most senior health + wellness communicators well-versed in navigating issues and crisis-rich environments, this strategic…
Read MoreCEO of Epilepsy Action Australia slams “appalling” TikTok ‘seizure challenge’ trend
CEO of Epilepsy Action Australia, Carol Ireland, released a public statement yesterday, following a recent controversial viral trend on the video app TikTok, known as the “seizure challenge”. Ms Ireland commented she is “appalled that people are pretending to have seizures as if it’s a joke”. The latest challenge to have gone viral on TikTok,…
Read MoreTop tips for WFH video calls
How to avoid faux pas & respect your fellow zoomies Working from home presents unique challenges and opportunities for those fortunate enough to be able to do so. Businesses and their employees are doing their best to navigate these unprecedented times, so it’s important to practice patience and respect. Here at VIVA! we are doing…
Read MoreAussies & Kiwis with incurable blood cancer receive newly subsidised treatment option
Today, VIVA! partnered with Celgene, a Bristol-Myers Squibb company, Multiple Myeloma Australia and Multiple Myeloma New Zealand to announce a newly reimbursed treatment option for Australians and New Zealanders living with incurable blood cancer, multiple myeloma. REVLIMID® (lenalidomide) – the first and only maintenance treatment in ANZ specifically indicated and reimbursed for those with newly…
Read More